5304 篇
13870 篇
408840 篇
16091 篇
9269 篇
3870 篇
6469 篇
1239 篇
72413 篇
37119 篇
12061 篇
1622 篇
2824 篇
3387 篇
640 篇
1229 篇
1966 篇
4869 篇
3823 篇
5299 篇
重磅炸弹肿瘤品牌市场分析和分段预测到2027年
Blockbuster Oncology Brands Market Analysis and Segment Forecast to 2027
In the past decade, the U.S. FDA has approved approximately 47 new indications for nearly 35 oncology products under the accelerated approval process. Accelerated regulatory approvals allow faster launch of oncology products after achievement of surrogate endpoints, which enable these therapies to qualify for commercialization. Breakthrough therapy and orphan drug designations granted to therapies accelerate market access by an average time difference of nearly 4.7 years as compared to the regular clinical development pathway for biologics.
CHAPTER 01 Methodology and Scope
CHAPTER 02 Executive Summary
CHAPTER 03 Market Variables, Trends & Scope
CHAPTER 04 Market Definitions
CHAPTER 05 Industry Outlook
CHAPTER 06 BUSINESS ENVIRONMENT ANALYSIS
CHAPTER 07 Regulatory Forces
CHAPTER 08 Competitive & Vendor Landscape
CHAPTER 09 Brands Estimates and Trend Analysis
CHAPTER 010 Indication Estimates and Trend Analysis
CHAPTER 011 Regional Estimates and Trend Analysis
CHAPTER 012 COMPANY PROFILES
CHAPTER 013 Pipeline Analysis
索取原文[173 页]
027-87841330